Results 51 to 60 of about 27,184 (256)

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate

Pharmaceutical Fronts, 2023
(R)-Tenofovir phenyl ester ((R)-1) and (R)-tenofovir diphenyl ester ((R)-2) are key intermediates for the practical synthesis of tenofovir alafenamide fumarate, which is a mainstay antiretroviral for the treatment of chronic hepatitis B and HIV-1 ...
Man Li, Ting Zhou, Qing-Wen Zhang
doaj   +1 more source

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results [PDF]

, 2016
Background BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects.
Avihingsanon, Anchalee, Echevarría, Juan, Gupta, Samir K., Hanna, George J., Joshi, Samit R., Lataillade, Max, Lombaard, John, McComsey, Grace A., Orrell, Catherine, Osiyemi, Olayemi, Ray, Neelanjana, Santoscoy, Mario, Stock, David A.   +12 more
core   +1 more source

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations

Alimentary Pharmacology &Therapeutics, EarlyView.
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Lung‐Yi Mak, Tsung‐Hui Hu, Desmond Y. H. Yap   +2 more
wiley   +1 more source

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. [PDF]

, 2019
"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood ...
Anton, Peter A, Deming, Timothy, Elliott, Julie, Fulcher, Jennifer A, Ibarrondo, F Javier, Kickhoefer, Valerie A, Maynard, Heather D, Mrazek, Jan, Rome, Leonard H, Tamshen, Kyle, Wollenberg, Alexander L, Yang, Otto O   +11 more
core  

Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: From treatment to prevention [PDF]

, 2013
The HIV epidemic continues unabated, with no highly effective vaccine and no cure. Each new infection has significant economic, social and human costs and prevention efforts are now as great a priority as global antiretroviral therapy (ART) scale up ...
A Bedri, A Calmy, A Coovadia, A Coovadia, A De Luca, A Hill, A Kunz, A Moorthy, A Moorthy, A Shibata, A Zolopa, AN Phillips, AY Liu, BE Nichols, BE Nichols, BG Brenner, BR Yehia, C Laurent, C Pretorius, C Unge, C Unge, C Zeh, CA Boucher, CB Hurt, CJ Hoffmann, CL Townsend, CS Chasela, D Descamps, D Frentz, D Frentz, D Persaud, DA van de Vijver, DA van de Vijver, DADS Group, DAMC Van de vijver, David A M C Van de Vijver, DC Vissers, DE Bennett, DJ McColl, E Arrive, E Bendavid, E Mills, EM Connor, ER Cooper, ES Daar, F Doualla-Bell, F Tanser, F van Leth, F van Leth, FA Frankel, FDA, FJ Palella Jr, G Jourdain, G Jourdain, GL Melikian, GN Nikolenko, H Sunpath, HM Coovadia, I de Vincenzi, I Thior, J Bor, J Fogel, J Marrazzo, J Mermin, J Mermin, J Ren, J Vercauteren, JA Hontelez, JA McIntyre, JB Nachega, JE Gallant, JE Gallant, JM Baeten, JM Baeten, JM Fogel, JM Whitcomb, JO Kahn, Joint United Nations Programme on HIV/AIDS (UNAIDS), JW Eaton, KA Delviks-Frankenberry, KN Althoff, L Ryom, L Van Damme, L Wittkop, LA Guay, M Lallemant, M Mirochnick, MA Fischl, MA Thompson, MA Wainberg, Mark A Wainberg, MC Hosseinipour, MC Thigpen, MD Miller, MS Cohen, N Ford, N Shaffer, N Sood, NA Martinson, NA Wade, NE Mackie, NI Kumwenda, P Mugyenyi, PR Meyer, Q Abdool Karim, R Granich, R Gupta, R Kaplan, Ravindra K Gupta, RE Barth, RF Schinazi, RF Schinazi, RK Gupta, RK Gupta, RL Hamers, RL Hamers, RL Shapiro, RM Granich, RM Grant, RM Gulick, RM Mainardes, RS Veazey, S Lockman, S Loubser, S Rosen, S Staszewski, S Staszewski, S Sungkanuparph, S Yerly, SH Eshleman, SH Yap, Sheetal Manicklal, SL Spruance, T Flys, U CHIC, UL Abbas, UM Parikh, UNAIDS, UNAIDS, V Cambiano, V von Wyl, VD Lima, VS Gill, WHO, WHO, Z Shubber   +145 more
core   +4 more sources

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann, Ulrike Wieland, Steffi Silling, Frank Oellig, David Chromy, Julia Hyun, Thilo Gambichler, Alexander Kreuter   +7 more
wiley   +1 more source

Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort

HIV Medicine
Most treatment switches are for simplification from three‐drug (3DR) to dual regimens (2DR). However, a proportion of people with HIV may switch back to 3DR, like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after 2DR.
A. De Vito, A. Tavelli, A. Cozzi-Lepri, Andrea Giacomelli, R. Rossotti, G. Ponta, N. Bobbio, A. Ianniello, A. Cingolani, G. Madeddu, Andrea Antinori, Antonella d’Arminio Monforte   +11 more
semanticscholar   +1 more source

Late diagnosis of paediatric HIV infection in high‐income countries: Lessons from the HIV Perinatal Virtual Clinic

HIV Medicine, EarlyView.
Abstract Introduction Timely diagnosis of HIV in children remains a challenge in all settings including low‐prevalence, high‐income countries (HIC). We aimed to characterize the prevalence of late diagnosis, and prior missed diagnostic opportunities among new presentations of paediatric HIV in HIC referred to an international Perinatal Virtual Clinic ...
Carolina Curto, M. Tritzali, A. Bamford, A. C. Bailey, E. G. H. Lyall, N. E. Mackie, N. Tickner, C. Foster, on behalf of the PVC   +8 more
wiley   +1 more source

Prospective study to assess progression of renal markers after interruption of tenofovir due to nephrotoxicity [PDF]

, 2016
Background. Prospective studies about the reversibility of tenofovir disoproxil fumarate- (TDF-) related renal impairment remain scarce. Methods. This is an observational prospective study including all patients that presented at our HIV Unit who ...
Bonjoch Badia, Anna, Clotet Sala, Bonaventura, Echeverria Liras, Patricia, Estany Quera, Carla, Negredo Puigmal, Eugènia, Puig, Jordi, Pérez Álvarez, Nuria   +6 more
core   +5 more sources

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source